Dr. Furth's research focuses on elucidation of biological mechanisms in cancer progression and regression, utilization of that information to better effect cancer prevention, and development of new research technologies. Over the past 15 years her laboratory has defined critical signaling nodes in mammary epithelial cell proliferation, survival and neoplastic progression in vivo. Most recently, her laboratory developed novel genetically engineered mouse models of estrogen-pathway-induced breast cancer that develop luminal A and B, Her2 and triple negative sub-types. These validated models are used to investigate genetic factors that modify breast cancer risk and response to chemopreventatives. A current research focus is to identify biomarkers of chemopreventative response and mechanisms of resistance that develop in preneoplasia following chemopreventative exposure. She was the first to demonstrate how the tetracycline-responsive gene expression system could be use in genetically engineered mice to temporally control gene expression and study cancer pathogenesis, and is the patent-holder for the use of jet injection for somatic cell gene transfer.